CIK 0001213037
- Non-accelerated filer
- Smaller reporting company
Cardiff Oncology, Inc.
Sign in to watch- Ticker
- CRDF
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272004382
- Phone
- +1 858-952-7570
- Business address
- 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
- Former names
- Trovagene, Inc., TrovaGene Inc., XENOMICS INC, USED KAR PARTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 65 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-01-02 | Billings Paul Director | Exercise or conversion · Restricted Stock Units | −16,667 | 0 | ||
| 2018-01-02 | Erlander Mark Chief Scientific Officer | Exercise or conversion | +18,750 | 66,855 | ||
| 2018-01-02 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −9,558 | 57,297 | ||
| 2018-01-02 | Erlander Mark Chief Scientific Officer | Exercise or conversion · Restricted Stock Units | −18,750 | 146,250 | ||
| 2018-01-02 | BRANCACCIO JOHN P Director | Exercise or conversion | +16,667 | 43,167 | ||
| 2018-01-02 | BRANCACCIO JOHN P Director | Exercise or conversion · Restricted Stock Units | −16,667 | 0 | ||
| 2018-01-02 | Tennant Stanley Director | Exercise or conversion | +16,667 | 234,545 | ||
| 2018-01-02 | Tennant Stanley Director | Exercise or conversion · Restricted Stock Units | −16,667 | 0 | ||
| 2018-01-02 | WELCH WILLIAM J Chief Executive Officer | Exercise or conversion | +50,000 | 795,392 | ||
| 2018-01-02 | WELCH WILLIAM J Chief Executive Officer | Shares withheld for taxes | −25,487 | 769,905 | ||
| 2018-01-02 | WELCH WILLIAM J Chief Executive Officer | Exercise or conversion · Restricted Stock Units | −50,000 | 280,000 | ||
| 2018-01-02 | Billings Paul Director | Exercise or conversion | +16,667 | 16,667 | ||
| 2018-01-02 | Billings Paul Director | Exercise or conversion · Restricted Stock Units | −16,667 | 0 | ||
| 2018-01-02 | ADAMS THOMAS PHD Director | Exercise or conversion | +16,667 | 351,959 | ||
| 2018-01-02 | ADAMS THOMAS PHD Director | Exercise or conversion · Restricted Stock Units | −16,667 | 0 | ||
| 2018-01-02 | JACOB GARY S Director | Exercise or conversion | +16,667 | 148,954 | ||
| 2018-01-02 | JACOB GARY S Director | Exercise or conversion · Restricted Stock Units | −16,667 | 0 | ||
| 2018-01-02 | Erlander Mark Chief Scientific Officer | Exercise or conversion | +18,750 | 66,801 | ||
| 2018-01-02 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −9,558 | 57,243 | ||
| 2018-01-02 | Erlander Mark Chief Scientific Officer | Exercise or conversion · Restricted Stock Units | −18,750 | 146,250 |
Page 12 of 15 · 299 trades